<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559230</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS# 20-0102</org_study_id>
    <secondary_id>HSC20200576X</secondary_id>
    <nct_id>NCT04559230</nct_id>
  </id_info>
  <brief_title>Sacituzumab Govitecan in Recurrent Glioblastoma</brief_title>
  <official_title>A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label single arm study. All patients will receive the investigational agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months</time_frame>
    <description>A single-arm two-stage Phase II Bayesian adaptive study of Sacituzumab Govitecan will be carried out in the expansion phase based on progression free survival at 6 months with unfavorable and favorable probabilities of 0.17 and 0.34, respectively.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Sacituzumab govitecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan</intervention_name>
    <description>Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.</description>
    <arm_group_label>Sacituzumab govitecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Ability to understand the purposes and risks of the study and has signed a written&#xD;
             informed consent form approved by the investigator's IRB/Ethics Committee&#xD;
&#xD;
          -  Histologically confirmed IDH wild-type (de novo) GBM&#xD;
&#xD;
          -  Progression following standard combined modality treatment with radiation and&#xD;
             temozolomide chemotherapy if O6-Methylguanine-DNA Methyltransferase (MGMT) methylated;&#xD;
             prior temozolomide is not required for MGMT unmethylated, but patient must have&#xD;
             received standard doses of radiation. Inclusion of additional investigational therapy&#xD;
             with standard therapy is not exclusionary. No additional lines of therapy.&#xD;
&#xD;
          -  Patients may have had been operated for recurrence, but if operated must have had&#xD;
             surgery a minimum of 2 weeks prior to enrollment and have an MRI completed within 48&#xD;
             hours following surgery.&#xD;
&#xD;
          -  No radiotherapy within the three months prior to the diagnosis of progression.&#xD;
&#xD;
          -  Willingness to forego tumor treatment field (Optune) therapy during participation in&#xD;
             the study.&#xD;
&#xD;
          -  Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.&#xD;
&#xD;
          -  Recovered from toxicities of prior therapy to grade 0 or 1, except for neuropathy&#xD;
             (≤Grade 2) and alopecia.&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Acceptable liver function:&#xD;
&#xD;
               1. Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
               2. AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);&#xD;
&#xD;
          -  Acceptable renal function:&#xD;
&#xD;
             a. creatinine clearance ≥30 mL/minute according to the Cockcroft and Gault formula&#xD;
&#xD;
          -  Acceptable hematologic status (without hematologic support):&#xD;
&#xD;
               1. ANC ≥1500 cells/uL&#xD;
&#xD;
               2. Platelet count ≥100,000/uL&#xD;
&#xD;
               3. Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
          -  All women of childbearing potential must have a negative serum pregnancy test and male&#xD;
             and female subjects must agree to use effective means of contraception (surgical&#xD;
             sterilization or the use or barrier contraception with either a condom or diaphragm in&#xD;
             conjunction with spermicidal gel or an IUD) with their partner from entry into the&#xD;
             study through 6 months after the last dose&#xD;
&#xD;
          -  Availability of biological material for central review and biomarker evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling&#xD;
             inhibitors&#xD;
&#xD;
          -  The subject is receiving warfarin (or other coumarin derivatives) and is unable to&#xD;
             switch to low molecular weight heparin (LMWH) before the first dose of study drug.&#xD;
&#xD;
          -  The subject has evidence of acute intracranial or intratumoral hemorrhage either by&#xD;
             MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes,&#xD;
             punctate hemorrhage, or hemosiderin are eligible.&#xD;
&#xD;
          -  The subject is unable to undergo MRI scan (eg, has pacemaker).&#xD;
&#xD;
          -  The subject has received enzyme-inducing anti-epileptic agents within 14 days of study&#xD;
             drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).&#xD;
&#xD;
          -  The subject has not recovered to National Cancer Institute (NCI) Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) 5.0 Grade ≤ 1 from AEs (except alopecia, anemia&#xD;
             and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or&#xD;
             other medications that were administered prior to study drug.&#xD;
&#xD;
          -  The subject is pregnant or breast-feeding.&#xD;
&#xD;
          -  The subject has serious intercurrent illness, such as:&#xD;
&#xD;
               -  hypertension (two or more blood pressure [BP] readings performed at screening of&#xD;
                  &gt; 150 mmHg systolic or &gt; 100 mmHg diastolic) despite optimal treatment&#xD;
&#xD;
               -  non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  significant cardiac arrhythmias&#xD;
&#xD;
               -  untreated hypothyroidism&#xD;
&#xD;
               -  unhealed rectal or peri-rectal abscess&#xD;
&#xD;
               -  uncontrolled active infection&#xD;
&#xD;
               -  symptomatic congestive heart failure or unstable angina pectoris within 3 months&#xD;
                  prior study drug any history of cardiac arrhythmia or heart block&#xD;
&#xD;
               -  stroke or transient ischemic attack within 6 months&#xD;
&#xD;
          -  The subject has received any of the following prior anticancer therapy:&#xD;
&#xD;
               -  Non-standard radiation therapy such as brachytherapy, systemic radioisotope&#xD;
                  therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic&#xD;
                  radiosurgery (SRS) is allowed&#xD;
&#xD;
               -  Systemic therapy (including investigational agents and small-molecule kinase&#xD;
                  inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5&#xD;
                  half-lives, whichever is shorter, prior first dose of study drug&#xD;
&#xD;
               -  Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21&#xD;
                  days prior to first dose of study drug&#xD;
&#xD;
               -  Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose&#xD;
                  chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days,&#xD;
                  prior to first dose of study drug&#xD;
&#xD;
               -  Prior treatment with carmustine wafers&#xD;
&#xD;
          -  Patients with radiographically apparent leptomeningeal involvement are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mays Cancer Center, UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-1000</phone>
    <email>goodwine@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eudocia Quant Lee, MD, MPH</last_name>
      <email>EQLEE@PARTNERS.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harold C. Simmons Comprehensive Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Edward Pan, MD</last_name>
      <email>Edward.Pan@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

